CN108567994A - 一种改性胶原膜及其应用 - Google Patents

一种改性胶原膜及其应用 Download PDF

Info

Publication number
CN108567994A
CN108567994A CN201810698688.3A CN201810698688A CN108567994A CN 108567994 A CN108567994 A CN 108567994A CN 201810698688 A CN201810698688 A CN 201810698688A CN 108567994 A CN108567994 A CN 108567994A
Authority
CN
China
Prior art keywords
membrane
collagen
modified
epigallo
egcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810698688.3A
Other languages
English (en)
Inventor
满毅
朱宸佑
向琳
邓佳
屈依丽
刘丽
周寅
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan University
Original Assignee
Sichuan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan University filed Critical Sichuan University
Priority to CN201810698688.3A priority Critical patent/CN108567994A/zh
Publication of CN108567994A publication Critical patent/CN108567994A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A61L2300/414—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)

Abstract

本发明提供了一种改性胶原膜，制备方法如下：由表没食子儿茶素没食子酸酯交联胶原膜；加载白细胞介素‑4至步骤A得到的胶原膜，清洗，干燥，即得。本发明的优点在于：本发明用白细胞介素‑4和表没食子儿茶素没食子酸酯改性胶原膜后，拥有更好的能力诱导颅顶骨缺损的修复。提高了以前胶原膜的生物性能，具有很好的应用前景，为引导再生术等相关增量手术提供了新选择。

Description

一种改性胶原膜及其应用
技术领域
本发明属于生物材料领域，具体涉及一种改性胶原膜及其应用。
背景技术
牙科手术中常需要应用引导骨再生手术进行骨增量。胶原是细胞外基质的一种成分，已 经广泛应用于引导骨再生术中。胶原膜有较好的生物兼容性，并能促进成骨细胞黏附、增殖、 迁移和分化，也能有阻挡成纤维细胞快速入侵骨组织生长位点、隔开软组织与硬组织的生长 等屏障功能。
然而，作为一种外源性移植物，胶原仍然会引起一定的炎症反应，同时也因为它的易降 解性而缺乏较好的机械性能。本领域常用采用戊二醛与胶原进行交联，从而提高它的机械性 能，但容易引发炎症和产生细胞毒性。因此，胶原膜长期的保存和使用，不仅仅需要提高机 械性能，更要抗炎和提高生物兼容性。
发明内容
本发明的目的是针对现有技术中存在的不足，提供一种改性胶原膜及其应用。
为了达到上述目的，本发明采用了下列技术方案：一种改性胶原膜，制备方法如下：
A.由表没食子儿茶素没食子酸酯交联胶原膜；
B.加载白细胞介素-4至步骤A得到的胶原膜，清洗，干燥，即得。
作为优选，所述的胶原膜为牛来源I型胶原制备得到。
作为优选，所述步骤A中，表没食子儿茶素没食子酸酯和胶原膜的重量比为1：100。
作为优选，所述步骤A中，交联是将胶原置于表没食子儿茶素没食子酸酯中改性60min， lX PBS缓冲液冲洗。
作为优选，所述步骤A中，胶原膜是在-26℃温度下冷冻过夜；在-53℃、1Pa条件下，真 空冷冻干得到。
作为优选，所述步骤B中，加载为按照100mg：1ml的比例，将胶原膜浸泡在浓度为500ng/ml的白细胞介素-4的水溶液中，浸泡时间为24小时。
作为优选，所述步骤B中，干燥为将制备好的改性胶原膜置于-20℃条件下冷冻干燥过夜。
所述改性胶原在医疗领域的应用。
表没食子儿茶素没食子酸酯是一种茶多酚，拥有抗癌、抗氧化、抗炎、抗纤维化和促骨 再生的作用。并且，表没食子儿茶素没食子酸酯能提高胶原的热稳定性，并保护胶原不被胶 原酶降解，因此它可以用于胶原膜的交联。
近年来，基于巨噬细胞极化的生物材料获得了广泛关注。近期研究表明，巨噬细胞大致 分为两类：促炎型(M1)巨噬细胞和促生长型(M2)巨噬细胞。M1型巨噬细胞由干扰素-γ和脂多糖诱导激活，分泌促炎因子，并参与细胞免疫和组织损伤。与之相反，M2型巨噬细胞由白细胞介素-4诱导激活，分泌抗炎因子白介素-10，并在体液免疫、过敏反应、抗寄生虫反应和组织修复中起到重要作用。
本发明的优点在于：本发明创造性用白细胞介素-4和表没食子儿茶素没食子酸酯改性胶 原膜后，拥有更好的能力诱导颅顶骨缺损的修复。提高了以前胶原膜的生物性能，具有很好 的应用前景，为引导再生术等相关增量手术提供了新选择。
具体实施方式
下面对本发明作详细的说明。
为了使本发明的目的、技术方案及优点更加清楚明白，以下结合实施例，对本发明进行 进一步详细说明。应当理解，此处所描述的具体实施例仅仅用以解释本发明，并不用于限定 本发明。
实施例1：一种改性胶原膜，包括如下制备步骤：
A.由表没食子儿茶素没食子酸酯交联胶原膜；
B.加载白细胞介素-4至步骤A得到的胶原膜，清洗，干燥，即得。
实施例2：一种改性胶原膜，制备方法如下：
A.由表没食子儿茶素没食子酸酯交联胶原膜；
B.加载白细胞介素-4至步骤A得到的胶原膜，清洗，干燥，即得。
所述的胶原膜为牛来源I型胶原制备得到。
所述步骤A中，表没食子儿茶素没食子酸酯和胶原膜的重量比为1：100。
所述步骤A中，交联是将胶原置于表没食子儿茶素没食子酸酯中改性60min，lXPBS缓 冲液冲洗。
所述步骤A中，胶原膜是在-26℃温度下冷冻过夜；在-53℃、1Pa条件下，真空冷冻干得 到。
所述步骤B中，加载为按照100mg：1ml的比例，将胶原膜浸泡在浓度为500ng/ml的白 细胞介素-4的水溶液中，浸泡时间为24小时。
所述步骤B中，干燥为将制备好的改性胶原膜置于-20℃条件下冷冻干燥过夜。
本发明并不局限于前述的具体实施方式。本发明扩展到任何在本说明书中披露的新特征 或任何新的组合，以及披露的任一新的方法或过程的步骤或任何新的组合。

Claims (8)

1.一种改性胶原膜，其特征在于制备方法如下：
A.由表没食子儿茶素没食子酸酯交联胶原膜；
B.加载白细胞介素-4至步骤A得到的胶原膜，清洗，干燥，即得。
2.根据权利要求1所述的一种改性胶原，其特征在于：所述的胶原膜为牛来源I型胶原制备得到。
3.根据权利要求1所述的一种改性胶原，其特征在于：所述步骤A中，表没食子儿茶素没食子酸酯和胶原膜的重量比为1：100。
4.根据权利要求1所述的一种改性胶原，其特征在于：所述步骤A中，交联是将胶原置于表没食子儿茶素没食子酸酯中改性60min，lX PBS缓冲液冲洗。
5.根据权利要求1所述的一种改性胶原，其特征在于：所述步骤A中，胶原膜是在-26℃温度下冷冻过夜；在-53℃、1Pa条件下，真空冷冻干得到。
6.根据权利要求1所述的一种改性胶原，其特征在于：所述步骤B中，加载为按照100mg：1ml的比例，将胶原膜浸泡在浓度为500ng/ml的白细胞介素-4的水溶液中，浸泡时间为24小时。
7.根据权利要求1所述的一种改性胶原，其特征在于：所述步骤B中，干燥为将制备好的改性胶原膜置于-20℃条件下冷冻干燥过夜。
8.根据权利要求1-7任一所述的一种改性胶原，其特征在于：所述改性胶原在医疗领域的应用。
CN201810698688.3A 2018-06-29 2018-06-29 一种改性胶原膜及其应用 Pending CN108567994A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810698688.3A CN108567994A (zh) 2018-06-29 2018-06-29 一种改性胶原膜及其应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810698688.3A CN108567994A (zh) 2018-06-29 2018-06-29 一种改性胶原膜及其应用

Publications (1)

Publication Number Publication Date
CN108567994A true CN108567994A (zh) 2018-09-25

Family

ID=63573662

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810698688.3A Pending CN108567994A (zh) 2018-06-29 2018-06-29 一种改性胶原膜及其应用

Country Status (1)

Country Link
CN (1) CN108567994A (zh)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109331232A (zh) * 2018-10-25 2019-02-15 四川大学华西医院 一种表没食子儿茶素没食子酸酯交联的小肠黏膜下层引导骨再生膜的制备方法
CN111888531A (zh) * 2020-08-14 2020-11-06 广州润虹医药科技股份有限公司 一种引导性组织再生膜及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101998862A (zh) * 2008-02-12 2011-03-30 骨骼技术股份有限公司 人胶原产品和制备人胶原产品的方法
CN106390195A (zh) * 2016-11-16 2017-02-15 四川大学 一种胶原膜的改性方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101998862A (zh) * 2008-02-12 2011-03-30 骨骼技术股份有限公司 人胶原产品和制备人胶原产品的方法
CN106390195A (zh) * 2016-11-16 2017-02-15 四川大学 一种胶原膜的改性方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHENYU CHU等: "Evaluation of epigallocatechin-3-gallate(EGCG) cross-linked collagen membranes and concerns on osteoblasts", 《MATERIALS SCIENCE AND ENGINEERING C》 *
余元勋主编: "《中国分子骨质疏松症学》", 30 April 2016, 合肥：安徽科技出版社 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109331232A (zh) * 2018-10-25 2019-02-15 四川大学华西医院 一种表没食子儿茶素没食子酸酯交联的小肠黏膜下层引导骨再生膜的制备方法
CN111888531A (zh) * 2020-08-14 2020-11-06 广州润虹医药科技股份有限公司 一种引导性组织再生膜及其制备方法

Similar Documents

Publication Publication Date Title
CA2721507C (en) Methods of generating and using procollagen
Sun et al. Engineering pro‐regenerative hydrogels for scarless wound healing
Ruszczak Effect of collagen matrices on dermal wound healing
US6383220B1 (en) Artificial skin
JP5930476B2 (ja) 再生組織足場の製造
CN107998444B (zh) 一种皮肤修复气凝胶型敷料的制备方法及其应用
CN108567994A (zh) 一种改性胶原膜及其应用
Kilic Bektas et al. A bilayer scaffold prepared from collagen and carboxymethyl cellulose for skin tissue engineering applications
Schallberger et al. Effect of porcine small intestinal submucosa on acute full‐thickness wounds in dogs
Capella‐Monsonís et al. Decellularized xenografts in regenerative medicine: From processing to clinical application
Shi et al. Bladder regeneration in a canine model using a bladder acellular matrix loaded with a collagen-binding bFGF
Mohebichamkhorami et al. Skin substitutes; an updated review of products from year 1980 to 2017
Bush et al. Process development and manufacturing of human and animal acellular dermal matrices
Zhang et al. Cryopreserved skin epithelial cell sheet combined with acellular amniotic membrane as an off-the-shelf scaffold for urethral regeneration
Sharma et al. Updates on recent clinical assessment of commercial chronic wound care products
JPWO2002045767A1 (ja) 組織再生用基材、移植用材料及びそれらの製法
CN108785744A (zh) 一种改性胶原膜及其应用
Perez-Lopez et al. Stem cell and tissue engineering approaches in pressure ulcer treatment
Yonezawa et al. Clinical study with allogeneic cultured dermal substitutes for chronic leg ulcers
Tanaka et al. Allogeneic cultured dermal substitute composed of spongy collagen containing fibroblasts: evaluation in animal test
CN109096520A (zh) 一种改性胶原及其制备方法
Lantis et al. Topical wound care treatment and indications for their use
WO2020228733A1 (en) Extracellular matrix material and uses thereof
Allen et al. Full-thickness oral mucoperiosteal defects: challenges and opportunities
Yamada et al. Clinical trial of allogeneic cultured dermal substitutes for intractable skin ulcers of the lower leg

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20180925

RJ01 Rejection of invention patent application after publication